Spotlight on tumors: new scan could personalize cancer treatment
NCT ID NCT06383598
First seen Apr 09, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study is testing a new imaging agent called [68Ga]Ga-THP-PDL1-3 that lights up a protein (PD-L1) on cancer cells during a PET/CT scan. The goal is to see where and how much PD-L1 is present in tumors, which could help doctors choose the right treatments and monitor changes over time. About 50 adults with solid tumors will participate to check if the scan is safe and works well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.